| 분자 | Cat. No. | Product Name | 종 | Host | 구조 | 순도 | Activity | 규격 및 가격 |
|---|---|---|---|---|---|---|---|---|
| HLA-A*0201 & B2M & hTERT (ILAKFLHWL) | Biotinylated Human HLA-A*02:01&B2M&hTERT (ILAKFLHWL) Complex Protein (Monomer, MALS verified) |  Human | HEK293 | MALSSDS-PAGE | $125.00 25ug | |||
| HLA-A*0201 & B2M & hTERT (ILAKFLHWL) | APC-Labeled Human HLA-A*02:01&B2M&hTERT (ILAKFLHWL) Tetramer Protein | Human | HEK293 | $410.00 25ug | ||||
| HLA-A*0201 & B2M & hTERT (ILAKFLHWL) | PE-Labeled Human HLA-A*02:01&B2M&hTERT (ILAKFLHWL) Tetramer Protein | Human | HEK293 | $410.00 25ug |
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| JWATM-203 | JWATM-203; JWATM203 | Phase 2 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Carcinoma, Hepatocellular | 상세 |
| SynOV1.1 | Phase 2 Clinical | Beijing Syngentech Co Ltd | Solid tumours; Carcinoma, Hepatocellular | 상세 | |
| ET140203 | Phase 2 Clinical | Eureka Therapeutics Inc | Liver Neoplasms; Hepatoblastoma; Carcinoma, Hepatocellular | 상세 | |
| Alpha fetoprotein targeted T-cell therapy (Adaptimmune) | AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332T | Phase 1 Clinical | Adaptimmune Llc | Liver Neoplasms | 상세 |
| HRYZ-T102 | HRYZ-T102 | Phase 1 Clinical | Hengrui Yuanzheng (Shanghai) Biotechnology Co Ltd | Solid tumours; Carcinoma, Hepatocellular | 상세 |
| ET1402L1-CART | AFP/ET-1402; ET1402; ET-1402; AFP-CAR; ET-140202 | Phase 1 Clinical | Eureka Therapeutics Inc | Liver Neoplasms; Carcinoma, Hepatocellular | 상세 |
| TAEST-1901 | TAEST-1901 | Phase 1 Clinical | Xiangxue Life Science Technology (Guangdong) Co Ltd | Liver Neoplasms; Neoplasms | 상세 |
| ET1402L1-ARTEMIS T cells | Phase 1 Clinical | Aeon Therapeutics (Beijing) Co Ltd | Liver Neoplasms; Carcinoma, Hepatocellular | 상세 | |
| CPU-118 | CPU-118 | Phase 1 Clinical | China Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co Ltd | Liver Neoplasms; Solid tumours; Neoplasms | 상세 |
